You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 21, 2024

CLINICAL TRIALS PROFILE FOR LAPAQUISTAT


✉ Email this page to a colleague

« Back to Dashboard


Clinical Trials for Lapaquistat

Trial ID Title Status Sponsor Phase Summary
NCT00143663 ↗ Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol Completed Takeda Phase 3 The purpose of this study is to determine if patients with elevated cholesterol, but not taking any other lipid medication, could lower their cholesterol with administration of lapaquistat acetate, once daily (QD).
NCT00143676 ↗ Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia Completed Takeda Phase 3 The purpose of this study is to determine the efficacy of lapaquistat acetate, once daily (QD), on lowering cholesterol in subjects already taking atorvastatin.
NCT00249899 ↗ Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia Terminated Takeda Phase 3 The purpose of this study is to evaluate lapaquistat acetate, once daily (QD), taken alone or with additional statin therapy on cholesterol levels in treating patients with elevated cholesterol.
NCT00249912 ↗ Efficacy of Lapaquistat Acetate Alone or Combined With Rosuvastatin in Subjects With Hypercholesterolemia Completed Takeda Phase 3 The purpose of this study is to evaluate lapaquistat acetate, once daily (QD), taken alone or with rosuvastatin on cholesterol levels in treating patients with elevated cholesterol.
NCT00251680 ↗ Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy. Completed Takeda Phase 3 The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), taken with established lipid-lowering therapy in subjects with type 2 diabetes mellitus.
NCT00256178 ↗ Efficacy of Lapaquistat Acetate and Simvastatin in Subjects With Primary Dyslipidemia. Completed Takeda Phase 3 The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), taken with simvastatin on cholesterol levels in subjects with primary dyslipidemia
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Lapaquistat

Condition Name

Condition Name
Intervention Trials
Hypercholesterolemia 12
Dyslipidemia 2
Hyperlipidemias 1
Type 2 Diabetes 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH
Intervention Trials
Hypercholesterolemia 13
Dyslipidemias 4
Hyperlipoproteinemias 1
Hyperlipidemias 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Lapaquistat

Trials by Country

Trials by Country
Location Trials
United States 232
Canada 16
United Kingdom 7
Estonia 5
South Africa 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State
Location Trials
California 10
Kansas 10
Illinois 10
Ohio 9
Virginia 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Lapaquistat

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase Trials
Phase 3 13
Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase Trials
Completed 11
Terminated 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Lapaquistat

Sponsor Name

Sponsor Name
Sponsor Trials
Takeda 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type
Sponsor Trials
Industry 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.